Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis

Published: Wednesday, September 04, 2013
Last Updated: Wednesday, September 04, 2013
Bookmark and Share
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.

Imaxio has announced that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio’s IMX313.

The study will be performed in the UK and led by Prof. Helen McShane from the Jenner Institute at Oxford University.

Imaxio's proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of each vaccine in which it is used.

IMX313 brings significant potential as a solution to develop vaccines and immunotherapies for major indications. The technology was designed in response to the challenge in increasing the effectiveness of some human and animal health candidates.

It is currently used for the development of vaccine candidates indicated for influenza, Staphylococcus aureus infection, tuberculosis and malaria.

Tuberculosis remains a significant cause of mortality and morbidity throughout the developing world. Worldwide, there are two million deaths each year from TB. It is estimated that a third of the world’s population is latently infected with Mycobacterium tuberculosis, the bacteria responsible for tuberculosis.

The HIV epidemic and the emergence of multi-drug resistant strains of TB have made the need for improved tuberculosis control even more urgent.

As the currently available vaccine, BCG, is largely ineffective at protecting against adult pulmonary disease in endemic areas, the MVA85A vaccine candidate has been designed to enhance BCG’s protective efficacy.

Though first studies of MVA85A were promising, a recent phase II clinical trial revealed that the vaccine candidate did not offer extra protection against TB in South African infants who had already received the BCG vaccine.

The Jenner Institute is investigating a number of options to see if the immune response generated by MVA85A can be improved.

The Jenner Institute identified IMX313 as one of the best vaccine technologies to enhance immune responses in a comparison study funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative. It is now starting to evaluate it in humans in combination with MVA85A.

“Following a number of successes with IMX313 in preclinical trials, we are really pleased to have reached this milestone: the first administration of IMX313 in humans,” explains Dr. Fergal Hill, chief scientific officer of Imaxio. “We believe strongly that this will confirm fully that IMX313 is a real solution for developing more effective human vaccines and for addressing major infectious diseases.”

“We are keen to find out whether this novel vaccine candidate will pave the way for new successes in addressing tuberculosis,” said Prof. Helen McShane, tuberculosis program leader and professor of vaccinology at the Jenner Institute at Oxford University. “We think IMX313 may be a key component to help MVA85A show even greater potency in humans.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Signs an Option for a License Agreement with DKFZ
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus.
Friday, October 17, 2014
Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
IMX313 has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial.
Monday, September 16, 2013
Imaxio Signs an Option for a License Agreement with Merial
This option agreement confirms the potential of Imaxio’s antigen re-engineering technology to improve human and animal health vaccines.
Tuesday, December 18, 2012
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!